Dimensional Fund Advisors LP cut its holdings in Envista Holdings Co. (NYSE:NVST – Free Report) by 9.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,101,397 shares of the company’s stock after selling 632,000 shares during the period. Dimensional Fund Advisors LP owned about 3.55% of Envista worth $101,465,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the business. Brown Brothers Harriman & Co. boosted its stake in Envista by 24.3% in the second quarter. Brown Brothers Harriman & Co. now owns 14,300 shares of the company’s stock valued at $238,000 after acquiring an additional 2,800 shares during the period. WINTON GROUP Ltd acquired a new position in Envista during the 2nd quarter valued at approximately $7,019,000. Diamond Hill Capital Management Inc. grew its stake in Envista by 1.4% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,235,350 shares of the company’s stock worth $20,544,000 after buying an additional 16,922 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Envista by 1.1% in the second quarter. Envestnet Asset Management Inc. now owns 145,877 shares of the company’s stock worth $2,426,000 after buying an additional 1,648 shares during the period. Finally, Nuance Investments LLC lifted its stake in Envista by 47.2% in the second quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock valued at $117,048,000 after buying an additional 2,256,993 shares during the last quarter.
Insiders Place Their Bets
In related news, CFO Eric D. Hammes acquired 24,532 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $16.33 per share, for a total transaction of $400,607.56. Following the transaction, the chief financial officer now owns 24,532 shares of the company’s stock, valued at $400,607.56. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Stock Report on NVST
Envista Trading Down 1.2 %
Shares of Envista stock opened at $18.84 on Wednesday. The business has a fifty day simple moving average of $17.49 and a 200-day simple moving average of $18.46. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of -26.17 and a beta of 1.31. Envista Holdings Co. has a fifty-two week low of $15.15 and a fifty-two week high of $28.67. The company has a quick ratio of 1.90, a current ratio of 2.22 and a debt-to-equity ratio of 0.47.
Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.16). Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. The business had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. During the same quarter last year, the business posted $0.43 EPS. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. On average, equities analysts forecast that Envista Holdings Co. will post 0.69 EPS for the current fiscal year.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
- Five stocks we like better than Envista
- Using the MarketBeat Dividend Tax Calculator
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is the Dow Jones Industrial Average (DJIA)?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.